UVI 3003

• Description :

  UVI 3003 is a highly selective antagonist of retinoid X receptor (RXR), and inhibits xenopus and human RXRα in Cos7 cells, with IC50s of 0.22 and 0.24 μM, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; RAR/RXR

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Field of Research :

  Others

• Assay Protocol :

  https://www.medchemexpress.com/UVI_3003.html

• Purity :

  99.57

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CCCCCOC1=C(C2=CC(/C=C/C(O)=O)=CC=C2O)C=C3C(C(C)(CCC3(C)C)C)=C1

• Molecular Formula :

  C28H36O4

• Molecular Weight :

  436.58

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Zhu J, et al. The unexpected teratogenicity of RXR antagonist UVI3003 via activation of PPARγ in Xenopus tropicalis. Toxicol Appl Pharmacol. 2017 Jan 1;314:91-97.|[2]Hebert SL, et al. Effects of retinoic acid signaling on extraocular muscle myogenic precursor cells in vitro. Exp Cell Res. 2017 Dec 1;361 (1) :101-111.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [847239-17-2]